What Was Approved?
On July 24, 2026, the U.S. Food and Drug Administration approved Lytenava (bevacizumab-vikg) for the treatment of patients with neovascular, or wet, age-related macular degeneration (nAMD).
Lytenava is administered directly into the eye by a healthcare professional.
What Is Wet Age-Related Macular Degeneration?
Wet age-related macular degeneration is a condition that affects the macula, the central part of the retina responsible for detailed central vision.
In wet AMD, abnormal blood vessels can grow beneath or within the retina and may leak fluid or blood.
This can damage the macula and lead to changes in central vision.
How Does Lytenava Work?
Lytenava contains bevacizumab-vikg, a vascular endothelial growth factor, or VEGF, inhibitor.
VEGF contributes to the growth and leakage of abnormal blood vessels.
By inhibiting VEGF, Lytenava is intended to reduce abnormal blood-vessel activity associated with wet AMD.
How Is Lytenava Given?
According to the FDA-approved prescribing information, the recommended dose is:
1.25 mg in 0.05 mL administered by intravitreal injection once monthly, approximately every 28 days.
Intravitreal injection means the medicine is injected into the vitreous cavity inside the eye.
The injection should be administered by an appropriately qualified healthcare professional using proper aseptic technique.
Is Lytenava the Same as Intravenous Bevacizumab?
No.
Lytenava is specifically approved as bevacizumab-vikg for intravitreal use.
Other bevacizumab-containing products may have different approved indications, formulations, routes of administration, or labeling.
Patients should not assume that different bevacizumab products are interchangeable for every purpose.
Who Should Not Receive Lytenava?
The FDA-approved labeling lists contraindications that include:
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to bevacizumab-vikg or product components
A healthcare professional should evaluate these factors before treatment.
What Are the Important Safety Warnings?
The prescribing information includes several important warnings and precautions.
Endophthalmitis and Retinal Detachment
Intravitreal injections can be associated with serious eye complications, including endophthalmitis and retinal detachment.
Patients should promptly report symptoms that may indicate a serious eye problem, such as significant eye pain or sudden vision changes.
Increased Intraocular Pressure
An increase in pressure inside the eye can occur following an intravitreal injection.
The FDA labeling notes that increases in intraocular pressure have been observed within 60 minutes after injection.
Arterial Thromboembolic Events
Because Lytenava inhibits VEGF, the prescribing information also notes a potential risk of arterial thromboembolic events.
These may include serious cardiovascular or cerebrovascular events.
Individual risk should be considered by the treating clinician.
What Is the Most Common Side Effect?
In clinical studies, the most common adverse reaction reported in patients receiving Lytenava was conjunctival hemorrhage, occurring in about 4% of patients.
Conjunctival hemorrhage refers to bleeding beneath the clear surface covering the white part of the eye.
Other adverse effects may occur, so patients should review the complete prescribing information and report concerning symptoms to their eye specialist.
What Symptoms Should Be Reported Promptly?
Patients should seek prompt medical evaluation if they experience symptoms such as:
- Significant or worsening eye pain
- Sudden decrease in vision
- New flashes or floaters
- Increasing redness
- Unusual light sensitivity
- Other sudden or severe changes in vision
These symptoms can have several causes and require professional evaluation.
Why Is This Approval Important?
Lytenava adds another FDA-approved VEGF-inhibiting treatment option for patients with wet age-related macular degeneration.
Because untreated or inadequately controlled wet AMD can threaten central vision, treatment and follow-up with an eye specialist are important.
The FDA also lists Lytenava among its 2026 novel drug approvals.
Bottom Line
Lytenava (bevacizumab-vikg) is an FDA-approved intravitreal treatment for neovascular, or wet, age-related macular degeneration.
It is administered once monthly by injection into the eye and requires professional administration and monitoring because intravitreal injections can be associated with serious ocular complications.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Lytenava (bevacizumab-vikg) Prescribing Information, revised July 2026.
- U.S. Food and Drug Administration (FDA) — Lytenava Approval Letter, July 24, 2026.